INTRODUCTION
Melanoma is a malignant tumor of the skin and mucosae that requires early detection and excision to cure the patient. At the advanced stage melanoma is resistant to conventional therapies, and the survival rate for metastatic disease has not changed over the last 3 decades (1). On the other hand, melanoma belongs to the group of relatively immunogenic solid tumors with the highest rate of spontaneous regressions. Therefore, various immunotherapeutic approaches, including vaccination with tumor cells, are being evaluated in preclinical and clinical settings (2, 3) .
Cancer vaccines based on irradiated tumor cells provide a large spectrum of tumor antigens, including tumor-specific antigens that may stimulate broadly active immune response (4, 5) . Immunostimulatory properties of irradiated whole-cell vaccines depend on the uptake of tumor antigens by antigen presenting cells and their presentation in regional lymph nodes (LN) to activate antigen-specific (as well as bystander) helper and cytotoxic T cells (6) . Despite apparent advantages, whole cell melanoma vaccines cannot often prevent the development of various tumor-induced tolerance mechanisms due to low concentration of delivered antigens and insufficient signals for dendritic cell (DC) maturation (7) .
Transduction of vaccine cells with cytokine genes can substantially improve their immunogenicity (7) . In gene therapy experiments, interleukin (IL) 12 has been shown to be more effective in antitumor activity as compared with other cytokines used in the same schedule (8) . Locally secreted IL-12 stimulates proliferation and cytotoxicity of natural killer (NK) cells and T lymphocytes and promotes generation of Th1 effector cells (9, 10) . Due to induction of chemokines, IL-12 also exerts antiangiogenic effects decreasing blood supply to tumors (11) . Local continuous secretion of IL-12 at the tumor site allows avoiding toxicities related to systemic administration of recombinant IL-12 (12) .
In various murine tumor models vaccination with ex vivo IL-12 gene-transduced tumor cells exhibited potent antitumor response (13, 14) . Trials with IL-12 gene-modified melanoma cells have also been started in humans. Although the approach did not cause serious side effects, objective response rates have been far from expectations (2, 15) . Inadequate therapeutic effects may result from tumor escape mechanisms operating in patients with advanced melanoma who were selected for clinical studies. Melanoma cells, under the pressure of immune response mechanisms, undergo a process of immunoselection resulting in the loss of tumor-associated antigens, MHC, and costimulatory molecules. These alterations induce anergy or apoptosis of specific clones of CTLs (3, 6) . Therefore, the effectiveness and application of the IL-12 gene therapy in the treatment of melanoma may be improved by combination therapies or adjuvants enhancing insufficient antitumor response (16) . Thus far antitumor effects of IL-12 gene therapy have been increased by combinations with costimulatory molecules, interleukins, and chemokines (17) (18) (19) . Excellent candidates for the combined treatment with IL-12-secreting melanoma vaccine are synthetic oligodeoxynucleotides (ODN) containing CpG motifs. CpG motifs, responsible for immunostimulatory effects of bacterial DNA, contain unmethylated cytosine and guanine nucleotides, flanked by two specific bases on both ends. Additional modification of oligonucleotide, such as phosphorotioated backbone, provides resistance to enzymatic degradation (20, 21) . Recognition of CpG-ODN is mediated by Toll-like receptor 9, which triggers signaling pathways including mitogen-activated protein kinases and activates transcription factor nuclear factor B and activator protein. Cells that express TLR9 are composed of plasmacytoid DCs, B cells (in humans), as well as monocytes, macrophages, and myeloid DCs in mice (22, 23) .
ODN used in the present study, described as ODN 1826, has been successfully tested in various mouse vaccination models (24 -26) exerting antitumor effects on its own or when used as adjuvant for peptide vaccines and whole cell vaccines (27, 28) . Its excellent immunostimulatory properties are composed of stimulation of maturation and production of proinflammatory interleukins [IL-6, IL-12, and tumor necrosis factor (TNF)], chemokines, and IFNs (IFN-␣ and IFN-␤) by macrophages, DCs, and B lymphocytes. Indirectly, ODN 1826 also activates Th1 cells and NK cells and, thus, enhances adaptive immune response (22, 23) . Such properties strongly suggest that ODN 1826 may enhance antitumor effects of IL-12-secreting melanoma vaccine.
MATERIALS AND METHODS
Reagents. The CpG-ODN used in this study was a 20-mer termed 1826 (5ЈTCC ATG ACG TTC CTG ACG TT-3Ј) with a nuclease-resistant phosphorothioate backbone, which contains two CpG motifs known to have effective immunostimulatory properties on mouse immune system. As a control, ODN 1982 (5Ј-TCC AGG ACT TCT CTC AGG TT-3Ј) was used. Both ODNs were kindly provided by Dr. Arthur Krieg (Coley Pharmaceutical Group, Wellesley, MA). Recombinant mouse IL-12 (specific activity 4.6 ϫ 10 6 units/mg protein) was a generous gift from the Genetics Institute (Cambridge, MA). For in vitro experiments cytokines were diluted with 0.1% BSA (Sigma Chemicals, St. Louis, MO).
Mice. Breeding pairs of (C57BL/6xDBA/2)F1 mice, termed B6D2F1, 8 -12 weeks of age, were obtained from Inbred Mice Breeding Center of the Institute of Immunology and Experimental Medicine (Wrocław, Poland). Mice were kept in conventional conditions with full access to food and water during experiments. Animal studies were approved by the local regulatory agency.
Tumor Cells. The B78-H1 melanoma (herein named B78), a weakly immunogenic amelanotic subclone of murine B16 melanoma cell line, was kindly provided by Dr. Lloyd H. Graf (University of Chicago, Chicago, IL). Tumor cells were cultured in DMEM supplemented with 10% heat-inactivated FCS, antibiotics, 2-mercaptoethanol (50 M), and L-glutamine (2 mM) (all from Life Technologies, Inc. Ltd., Paisley, United Kingdom; culture medium) in a humidified atmosphere of 5% CO 2 .
IL-12-Expressing B78 Cells (B78/IL-12). Preparation of B78 melanoma cells secreting murine IL-12 has been performed as described elsewhere (17) . From among 12 clones of B78 cells transduced with the IL-12 gene, the clone "9" that produced the highest amount of IL-12 (272 pg/1 ϫ 10 6 cells/24 h, as determined by ELISA; Biosource International, Inc., Camarillo, CA), was denoted B78/IL-12 and used in experiments below.
In Vivo Experiments. For tumor implantation, mice were inoculated into the footpad of the right hind limb with 2 ϫ 10 5 B78 cells resuspended in 20 l of PBS (this dose of tumor cells is five times higher than the minimal LD 100 dose). In the therapeutic protocol mice with established B78 melanoma, on day 7 after tumor inoculation, were treated intratumorally with 1 ϫ 10 6 viable irradiated (45 Gy) B78/IL-12 cells [B78/IL-12(X)]. At that time tumors were not clearly visible, but the small area of the footpad allowed precise intratumoral injections. Then ODN 1826 was administered intratumorally in seven consecutive doses (2.5 g/mice) on days 10 -16. Each injection of ODN 1826 or B78/IL-12(X) cells was paralleled by intratumoral injection of 0.1% BSA-PBS into mice from the control group. In a prophylactic setting, mice were injected with B78/ IL-12(X) cells and ODN 1826 as in the therapeutic protocol and subsequently challenged with 2 ϫ 10 5 B78 cells the next day after the final injection of ODN 1826. Local tumor growth was established by measuring the diameter of the footpad (anteriorposterior dimension and side-to-side measure) with calipers every 3-4 days, starting from day 10 after inoculation of tumor cells. Tumor size was determined according to the formula: tumor diameter ϭ (diameter of footpad with growing tumor) Ϫ (diameter of nontreated contra-lateral footpad).
Histological Analysis of the Tumor. Mice were inoculated into the footpad of the right hind limb with 1 ϫ 10 6 B78 cells resuspended in 20 l of PBS. On day 7, when tumor nodules had approximate volume of 1 mm 3 , mice were treated according to the therapeutic protocol. One day after the final injection of CpG-ODN, tumors were surgically excised, fixed in 10% neutral-buffered formalin for 12-24 h at room temperature, and embedded in paraffin at 55°C. The 2-m-thick sections were stained by H&E, and the areas of necrosis and inflammatory infiltrations were evaluated. Two sections of each of the tumor were analyzed.
Spleen Cell Preparation. After tumor implantation, mice were treated according to the therapeutic protocol, and spleen cells were isolated 1 day after the last injection of ODN 1826. Single-cell suspensions were obtained by cutting spleens into small pieces and teasing with a glass tissue homogenizer, followed by lysis of erythrocytes by Tris-ammonium chloride. The cell suspensions were used for fluorescence-activated cell sorter analysis or cultured to detect cytokine secretion. For cytotoxicity assays splenocytes were additionally passed through nylon wool columns for B-cell depletion.
Flow Cytometric Analysis. The phenotype of lymphocytes from tumor-draining LNs and peritoneal cells was deter- Statistical Analysis. Differences between samples in tests in vitro and differences in tumor diameter in experiments in vivo were analyzed for significance by Student's t test (two-tailed). For the difference in complete tumor regressions, groups were analyzed by Wilcoxon's test. Additionally, to determine the difference in tumor take rate between groups, the 2 test was used.
RESULTS
Tumorigenicity of IL-12 Gene-Transduced B78/IL-12 Melanoma Cells. The initial experiments have shown that none of the mice inoculated into the footpad of the right hind limb with 1 ϫ 10 6 of IL-12 gene-transduced B78 melanoma cells secreting 272 pg/1 ϫ 10 6 /24 h developed tumor. Onefourth of them were additionally protected from a subsequent challenge with 1 ϫ 10 5 of B78 melanoma cells performed contralaterally 2 months after B78/IL12 cells inoculation (data shown elsewhere; Ref. 17) . Although B78/IL-12 cells turned out not to be tumorigenic, in additional experiments the cells were irradiated as described in "Materials and Methods" and denoted as B78/IL-12(X).
Inhibition of B78 Tumor Growth after Intratumoral Injections of ODN 1826. To investigate potential antitumor effects of ODN 1826, mice were inoculated s.c. into the right hind limb with 2 ϫ 10 5 B78 melanoma cells, and 6 days later CpG-ODN was injected intratumorally at the doses of 2.5 or 5 g for 7 consecutive days. Complete tumor rejections were observed in 75% of mice treated with a lower dose of CpG-ODN (data not presented) and in all of the mice treated with the dose of 5 g (Fig. 1) . The antitumor effect of CpG-ODN was dependent on the CpG motifs, because only marginal tumor growth inhibition was observed in mice treated with control ODN 1982 (Fig. 1 ). Systemic therapy with ODN 1826 (i.p. injections with 5 g/dose for 7 days) had no effect on tumor growth (data not shown). Therefore, in an attempt to optimize the B78/IL-12(X) vaccine-based therapeutic model we decided to start intratumoral injections of 2.5 g of ODN 1826 on day 10 after tumor inoculation. We found that such treatment significantly inhibited tumor growth but induced complete regressions in only about 10 -15% of mice (data not shown).
Intratumoral Treatment with B78/IL-12(X) Cells and ODN 1826 Induces Rejection of Established Tumors. To evaluate the antitumor effect of combination therapy with IL-12 gene-modified tumor vaccine and ODN 1826, B78 melanomabearing mice were treated according to the therapeutic protocol. As shown in Fig. 2, A and B , there was no difference in tumor progression and survival between vaccine-treated mice and control animals. Injections of ODN 1826 alone led to a marked inhibition of tumor growth. None of vaccine-treated mice rejected tumor completely, and only 1 of 7 mice (14%) treated with CpG-ODN experienced complete tumor regression (Fig.  2B) . In contrast, the combined treatment potently inhibited tumor growth (mean tumor diameter Ϯ SE on day 54: 0.78 Ϯ 0.42 versus 4.61 Ϯ 0.5 in controls). Additionally, in 5 of 8 mice Fig. 5B , none of the mice treated either with CpG-ODN alone or B78/IL-12(X) vaccine alone or from controls was protected against challenge with B78 cells. In contrast, 50% of the mice treated with combination of B78/IL-12(X) cells and CpG-ODN did not develop tumors within 2 months after inoculation of B78 melanoma cells.
Vaccination with B78/IL-12 Melanoma Cells and ODN 1826 Induces Lymphadenopathy of the Tumor-Draining LNs Resulting from a Marked Expansion of CD3
؊ CD19 ؉ , CD3 ؉ CD4 ؉ , and CD3 ؉ CD8 ؉ Cells. Macroscopically, a marked enlargement of LNs in B78/IL-12(X) vaccine-and/or ODN 1826-treated mice was observed, reflecting expansion of different lymphoid cell populations. The highest cellularity (an ϳ11-fold increase of the cell number in comparison with control mice) was observed in mice treated with B78/IL-12(X) vaccine and CpG-ODN together and, as shown in Fig. 6A, CD3 Ϫ CD19 ϩ population predominated among the cells in this group (not significant versus CpG alone-treated mice). Interestingly, the number of T cells defined as CD3 ϩ CD8 ϩ and CD3 ϩ CD4 ϩ cells was significantly higher in mice treated with B78/IL-12(X) ϩ ODN 1826 compared with mice treated with B78/IL-12(X) or CpG-ODN alone. The number of NK cell and macrophages was also raised in this group (a ϳ14-and 18-fold increase, respectively, versus controls) as well as in the group of mice treated with CpG-ODN alone (a ϳ16-and 11-fold increase, respectively, versus controls; Fig. 6B ).
There have been reports that treatment with CpG-ODN induces expansion or migration of DC (defined as CD11c ϩ ) to the regional LNs. Table 1 Cr release assay splenocytes from the B78/IL-12(X) vaccine-or ODN 1826-treated groups, restimulated in vitro with IL-2, exerted significant cytotoxic effect against B78 melanoma cells at ratios 50:1 and 25:1 compared with the control group. Splenocytes from the doubletreated mice were significantly more cytotoxic against parental B78 melanoma cells than splenocytes from B78/IL-12(X) vaccine-or Cr release assay (Fig. 7B) . To assess the effect of treatment with B78/IL-12(X) cells and/or ODN 1826 on IFN-␥ secretion by splenocytes, mice were treated as in the therapeutic protocol, and the next day after the last injection of CpG-ODN, spleen cells were isolated and incubated for 3 days, with B78(X) cells, IL-2, IL-12, or B78(X) in combination with IL-2. As shown in Fig. 8A , B78(X) cells stimulated strongly IFN-␥ production, especially in cultures of splenocytes from mice treated with a combination of B78/IL-12(X) vaccine and CpG-ODN. Although IL-2 alone did not induce IFN-␥ secretion in splenocytes, when applied with B78(X) cells, this cytokine significantly potentiated production of IFN-␥, particularly by splenocytes from mice treated with B78/IL-12(X) vaccine and CpG-ODN together. We also restimulated splenocytes with IL-12 to activate nonspecific cells. Again, the most potent stimulatory effect on IFN-␥ secretion was observed in cultures of splenocytes from mice after the combined therapy (Fig. 8A) . Additionally, TNF-␣ concentration in cultures of splenocytes restimulated with IL-12 was measured. We found that splenocytes from mice treated with combination of B78/IL-12(X) and ODN 1826, restimulated with IL-12, secreted significantly higher amounts of TNF-␣ in comparison with splenocytes from other groups of mice (Fig. 8B) .
Antitumor Activity of Macrophages from Mice Treated with ODN 1826. As shown in Fig. 8 , B78/IL-12(X) cells ϩ ODN 1826 strongly stimulated production of IFN-␥. Because this cytokine, in turn, potently stimulates macrophages and induces their tumoricidal activity, we decided to examine whether the combined treatment of mice with B78/IL-12 vaccine and/or ODN 1826 could produce similar effects in vivo. The data presented in Fig. 9 show that macrophages could contribute to the antitumor effects in mice treated with either B78/IL-12 cells ϩ ODN 1826 or ODN 1826 alone. Ex vivo peritoneal macrophages from ODN 1826-and double-treated mice inhibited proliferation of B78 melanoma cells in cultures more effectively than those from B78/IL-12(X) vaccine-treated mice and controls (P Ͻ 0.01). This effect was mediated, at least in part, by TNF-␣, because peritoneal macrophages stimulated (Fig. 10, A and B) . In contrast, expression of 
DISCUSSION
Impressive results of various immunotherapeutical approaches in animal models, including vaccines based on genetically modified tumor cells expressing cytokines, provoked numerous clinical trials using such treatment in humans. The majority of studies have been investigating melanoma, which is considered as one of the most immunogenic human tumors. Thus far, however, only one from among numerous vaccines clinically tested have been registered (Melacine in Canada, consisting of lysed melanoma allogeneic cell lines plus DETOX adjuvant; Ref.
3). In some clinical trials paradoxical discrepancy was observed: the induction of specific tumor-reactive cells after immunization did not correlate with the objective tumor regression (29, 30) . There is evidence that non-MHC-restricted inflammatory response, mediated by components of the innate immunity, can also play an important role in eliminating tumor cells and supporting the development of broadly active Th1 antitumor response (25) . The main rationale for combining CpG-ODN with B78/IL-12(X) vaccine in our studies was the assumption that by using CpG-ODN one is able to enhance local non-MHC-restricted (nonspecific) inflammatory response initiated by paracrine release of IL-12 from vaccine cells and to stimulate strongly development of specific T lymphocytes against tumor antigens derived from irradiated vaccine cells. We were also encouraged by results of other authors describing the synergistic effect of various immunotherapies in combination with IL-12 gene therapy (16) .
CpG-ODNs used in monotherapy were reported to induce rejection of various tumors (31, 32) . In the B78 melanoma model, which we have investigated, intratumoral treatment with ODN 1826 (Fig. 1) led to complete rejection of tumor cells probably due to activation of macrophages (33) . Analysis of peritoneal cells confirmed involvement of macrophages in this phenomenon and their potent tumoricidal activity (Fig. 9) despite the decreased expression of MHC molecules on their surface (34) . In concordance with findings of other authors (30) , for efficient activity of CpG-ODN, apart from the dose and its route of administration (local or intratumoral), other factors were also critical. Tumor load (determined by the time of the tumor development) is also crucial, because delayed initiation of the treatment may markedly diminish antitumor effect of CpG-ODN. Taking into account all of the above findings, we decided not to injected ODN 1826 simultaneously with irradiated vaccine cells secreting IL-12, but to use it 3 days after the vaccine and 10 days after tumor inoculation (to avoid untimely activation of CpG-induced innate response, which could accelerate destruction of vaccine cells and diminish the effect of locally secreted IL-12).
Vaccination with B78/IL-12(X) cells provides at least two stimuli for the immune system. Firstly, irradiated whole cells undergoing apoptosis deliver tumor antigens, which are phagocytosed by macrophages and DCs, processed and then presented by MHC molecules (4, 5). Secondly, paracrine secretion of IL-12 induce local inflammation by activation of NK, NK T cells, granulocytes, and T (T␥␦) lymphocytes infiltrating tumor to release such cytokines as IFN-␥, TNF-␣, IL-8, IL-15, IL-18, and granulocyte macrophage colony-stimulating factor (10, 35) . DCs accumulate at the site of inoculation of IL-12-releasing melanoma cells, which was demonstrated by other authors (14) . In our model, a single injection of B78/IL-12(X) vaccine was not sufficient to inhibit tumor growth despite the generation of cytotoxic effector cells in the spleen.
In contrast, intratumoral treatment with B78/IL-12(X) cells and ODN 1826 together induced tumor growth inhibition and rejection of established tumors in Ͼ60% of treated mice ( Fig.  2A) . Potentiated antitumor effect of the combined treatment may be related to concerted activation of host-specific and innate immune mechanisms, as proposed below.
Administration of CpG-ODN 3 days after vaccine injection (other authors usually inject vaccine/antigens and CpG-ODN at the same time; Refs. 27, 28) stimulates maturation of DCs (attracted to tumor by locally secreted IL-12; Ref. 36 ) and, by altering adhesion molecule pattern on their surface, induces DC migration to the peripheral LNs (23, 37) . This phenomenon could also account for the increased number of CD11c-positive cells (most probably DCs) in tumor-draining LNs in our studies (Table 1) . One may presume that mature DCs in the LNs successfully primed naïve T cells in our model (due to CpG-induced secretion of IL-12 at the level of LN) and stimulated their differentiation toward Th1 effectors. This would explain a marked increase in CD4 ϩ and CD8 ϩ cells in tumor-draining LNs in mice treated with a combination of the vaccine and ODN 1826 (Fig. 6A ). Our studies confirmed findings of other authors (31, 38) showing that ODN 1826 (as an example of CpG class B) also induces activation and proliferation of B lymphocytes (CD19-positive cells). We also observed an increased number of macrophages in tumor-draining LNs, which could result from chemotactic effect of CpG-ODN on these cells (39) . Activated macrophages and mature DCs secrete IL-12, TNF-␣, and IFN-␣. In turn, these cytokines stimulate NK cells and T-cell effectors to produce IFN-␥ (10), which was confirmed in our studies: splenocytes from double-treated mice released large amounts of IFN-␥. The synergistic effect of B78/IL-12(X) cell vaccine and ODN 1826 on IFN-␥ production suggests development of systemic immunity and supports the role of both Th1 and NK cells in this phenomenon. Both ODN 1826 and the vaccine were capable of inducing systemic immunity and generation of cytotoxic effectors in the spleen in our model (Fig. 7) , but this effect correlated with the antitumor response only in mice injected with ODN 1826. This finding suggests that CpG-ODN stimulates, besides specific immunity, other mechanisms (NK cells and granulocytes; Refs. 16, 38) . It should be stressed, however, that only the combined injection of B78/IL-12(X) melanoma cells and ODN 1826 stimulated systemic tumor cell immunity enough strongly to protect mice against parental B78 cells inoculated at distant sites and induced complete tumor regression in a significant proportion of mice. 6 ; day 0) and OND 1826 (2.5 g, daily, days 3-9) alone or in combination. On day 10, peritoneal macrophages were obtained as described in "Materials and Methods" and incubated with B78 melanoma cells for 3 days. Cytostatic/cytotoxic effect of macrophages on melanoma cells was tested in a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. ‫,ء‬ P Ͻ 0.001 and ‫,ءء‬ P Ͻ 0.01 versus macrophages from B78/IL-12(X) vaccine-treated mice and controls; bars, ϮSD. 6 ; day 0) and OND 1826 (2.5 g, daily, days 3-9), alone or in combination. On day 10, peritoneal macrophages were obtained as described in "Materials and Methods" and stained for CD80 molecules. A, B78/IL-12(X) vaccine and CpG-ODN; B, CpG-ODN; C, B78/IL-12(X) vaccine-treated mice; D, controls; m, mean fluorescence; PE, phycoerythrin.
